lapatinib has been researched along with Glial Cell Tumors in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 8 (72.73) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Chandratre, S; Chen, B; Howley, R; Mansi, M | 1 |
| Szymaszek, Ż; Twardowska, M; Uram, Ł; Walczak, M; Wołowiec, S; Wróbel, K | 1 |
| Blaney, SM; Boyett, JM; Fouladi, M; Gajjar, A; Geyer, JR; Gilbertson, RJ; Goldman, S; Kun, LE; Onar-Thomas, A; Packer, RJ; Schaiquevich, P; Stewart, CF | 1 |
| Cao, S; Chen, C; Chen, J; Gao, H; Jiang, X; Wang, Y; Wei, Y | 1 |
| Cao, S; Chen, C; Chen, J; Gao, H; Jiang, X; Xi, Z; Zhang, Q | 1 |
| Ali-Osman, F; Bigner, D; Buolamwini, J; Friedman, H; Haystead, T; Okamura, T; Singh, S | 1 |
| Argyriou, AA; Dimitrakopoulos, F; Dimitropoulos, K; Giannopoulou, E; Kalofonos, HP; Koutras, AK | 1 |
| Brennan, CW; Campos, C; Chang, SM; Chheda, MG; Cloughesy, TF; Dang, J; DeAngelis, LM; Drappatz, J; Fine, HA; Gilbert, MR; Grommes, C; Heguy, A; Horvath, S; Iwanami, A; Kubek, S; Kuga, D; Kuhn, JG; Lamborn, KR; Lassman, AB; Liau, LM; Lieberman, F; Mehta, MP; Mellinghoff, IK; Mischel, PS; Nghiemphu, PL; Oldrini, B; Pedraza, A; Prados, MD; Reardon, DA; Robins, HI; Rohle, D; Tao, H; Vivanco, I; Wen, PY; Wu, N; Yannuzzi, N; Yong, WH; Yung, WK; Zhu, S | 1 |
| Cao, S; Gao, H; Jiang, X; Pang, Z; Xi, Z; Yang, Z; Zhang, S | 1 |
| Bobos, M; Chrisafi, S; Fountzilas, G; Karavasilis, V; Kotoula, V; Lambaki, S; Pentheroudakis, G; Televantou, D | 1 |
| Barriuso, J; Curtis, CM; Dar, MM; de Bono, J; Groves, MD; Ma, B; McLendon, RE; Mikkelsen, T; Nabors, L; Raizer, J; Reardon, DA; Rosenfeld, S; Suttle, AB; Wen, PY | 1 |
3 trial(s) available for lapatinib and Glial Cell Tumors
| Article | Year |
|---|---|
A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study.
Topics: Adolescent; Antineoplastic Agents; Blotting, Western; Central Nervous System Neoplasms; Child; Child, Preschool; Ependymoma; ErbB Receptors; Female; Glioma; Humans; Infant; Lapatinib; Male; Medulloblastoma; Neoplasm Grading; Quinazolines; Treatment Outcome; Young Adult | 2013 |
A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Glioma; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Quinazolines; Temozolomide | 2013 |
A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma.
Topics: Adult; Angiogenesis Inhibitors; Anticonvulsants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease-Free Survival; Drug Delivery Systems; ErbB Receptors; Glioma; Humans; Indazoles; Lapatinib; Neoplasm Recurrence, Local; Neoplasm Staging; Pyrimidines; Quinazolines; Recurrence; Sulfonamides | 2013 |
8 other study(ies) available for lapatinib and Glial Cell Tumors
| Article | Year |
|---|---|
Inhibition of ABCG2 transporter by lapatinib enhances 5-aminolevulinic acid-mediated protoporphyrin IX fluorescence and photodynamic therapy response in human glioma cell lines.
Topics: Aminolevulinic Acid; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Line, Tumor; Ferrochelatase; Fluorescence; Glioma; Humans; Lapatinib; Neoplasm Proteins; Photochemotherapy; Photosensitizing Agents; Protoporphyrins | 2022 |
Exploring the Potential of Lapatinib, Fulvestrant, and Paclitaxel Conjugated with Glycidylated PAMAM G4 Dendrimers for Cancer and Parasite Treatment.
Topics: Animals; Caenorhabditis elegans; Carcinoma, Non-Small-Cell Lung; Dendrimers; Fulvestrant; Glioma; Humans; Lapatinib; Lung Neoplasms; Paclitaxel; Parasites | 2023 |
Incorporation of lapatinib into core-shell nanoparticles improves both the solubility and anti-glioma effects of the drug.
Topics: Animals; Area Under Curve; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Endocytosis; G2 Phase Cell Cycle Checkpoints; Glioma; Humans; Lapatinib; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Osteonectin; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Solubility; Survival Rate; Time Factors | 2014 |
In vivo behavior and safety of lapatinib-incorporated lipid nanoparticles.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Drug Carriers; Glioma; Injections, Intravenous; Lapatinib; Lethal Dose 50; Lipids; Male; Mice, Inbred ICR; Nanoparticles; Organ Specificity; Particle Size; Quinazolines; Rats, Sprague-Dawley; Solubility; Surface Properties; Tablets; Tissue Distribution | 2014 |
Tyrosine phosphorylation of the human glutathione S-transferase P1 by epidermal growth factor receptor.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Base Sequence; Binding Sites; Breast Neoplasms; Cell Line, Tumor; Cell-Free System; Cisplatin; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Female; Glioma; Glutathione S-Transferase pi; Humans; Lapatinib; Mice; Mice, Nude; Models, Molecular; Molecular Sequence Data; Neoplasm Transplantation; Phosphorylation; Protein Conformation; Quinazolines; Recombinant Proteins; RNA, Small Interfering; Signal Transduction; Static Electricity; Transplantation, Heterologous; Tyrosine | 2009 |
An in vitro study, evaluating the effect of sunitinib and/or lapatinib on two glioma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Glioma; Humans; Indoles; Lapatinib; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Pyrroles; Quinazolines; Sunitinib | 2010 |
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Humans; Lapatinib; Lung Neoplasms; Mice; Mutation; Protein Kinase Inhibitors; Quinazolines | 2012 |
Behavior and anti-glioma effect of lapatinib-incorporated lipoprotein-like nanoparticles.
Topics: Animals; Antineoplastic Agents; Body Weight; Cell Line, Tumor; Coumarins; Endocytosis; Fluorescent Antibody Technique; Glioma; Humans; Imaging, Three-Dimensional; In Situ Nick-End Labeling; Lapatinib; Lipoproteins; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Confocal; Nanoparticles; Osteonectin; Quinazolines; Receptor, ErbB-2; Subcellular Fractions; Xenograft Model Antitumor Assays | 2012 |